2. Cytoskeleton JAK/STAT Signaling Stem Cell/Wnt MAPK/ERK Pathway PI3K/Akt/mTOR
  3. Exosomes STAT ERK Akt
  4. Heart-homing peptide

Heart-homing peptide is a heart-targeting peptide with the sequence CRPPR that mediates cardiac endothelial targeting and accumulates in cardiac tissues. Heart-homing peptide mediates the translocation of liposomal and exosomal cargos across cardiac endothelium into interstitial tissues, enhances the accumulation of exosomes in the heart, and inhibits the GP130-STAT3/ERK1/2/AKT pathway. Heart-homing peptide accumulates at sites of ischemia/reperfusion, myocardial infarction and hypertrophy in mice. Heart-homing peptide can be used for the research of cardiovascular diseases.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Heart-homing peptide

Heart-homing peptide Chemical Structure

CAS No. : 876460-72-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Heart-homing peptide:

Other Forms of Heart-homing peptide:

Heart-homing peptide Related Antibodies

Top Publications Citing Use of Products

View All STAT Isoform Specific Products:

View All Isoforms
STAT3 STAT5 STAT6 STAT1

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Heart-homing peptide is a heart-targeting peptide with the sequence CRPPR that mediates cardiac endothelial targeting and accumulates in cardiac tissues. Heart-homing peptide mediates the translocation of liposomal and exosomal cargos across cardiac endothelium into interstitial tissues, enhances the accumulation of exosomes in the heart, and inhibits the GP130-STAT3/ERK1/2/AKT pathway. Heart-homing peptide accumulates at sites of ischemia/reperfusion, myocardial infarction and hypertrophy in mice. Heart-homing peptide can be used for the research of cardiovascular diseases[1][2][3].

In Vivo

Heart-homing peptide-exposed liposomes (7-60 mg/kg; i.v.; single dose) deliver cargo across intact murine cardiac endothelium efficiently, with peak accumulation and transport observed at a 20 mg/kg single i.v. dose, resulting in a 47-fold increase in cardiac tissue fluorescence relative to non-targeted liposomes within 30 minutes[1].
Exosomes displaying heart-homing peptide (4 mg/kg; i.v.; every third day; 7 doses total) preferentially accumulate in mouse hearts, significantly improve cardiac function, reduce left ventricular hypertrophy and fibrosis, and normalize hypertrophy signaling molecules in TAC-induced cardiac hypertrophy, with effects mediated via miRNA-148a-dependent suppression of the GP130-STAT3/ERK1/2/AKT pathway[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: FVB (2-month old, male, 20-25 g)[1]
Dosage: 7 mg/kg; 20 mg/kg; 60 mg/kg
Administration: i.v.; single dose
Result: Achieved 47-fold greater fluorescence in cardiac tissue surrounding vascular lumens than non-targeted liposomes and 64-fold greater than free dye within 30 minutes of 20 mg/kg injection.
Increased tissue, endothelial, and punctate fluorescence intensities from 7 mg/kg to 20 mg/kg, with no further increase at 60 mg/kg, indicating saturation of accumulation and trans-endothelial transport.
Maintained cardiac fluorescence intensity at ~40% of the 30-minute value at 24 hours post-injection, which was significantly greater than control groups.
Detected fluorescence above non-treated controls in 37.0% of endothelial (CD31+) cells, 0.63% of cardiomyocytes (MF20+), and 5.3% of fibroblasts (Thy1.1+) at 4 hours post-injection of 60 mg/kg liposomes.
Detected fluorescence above non-treated controls in 29.1% of endothelial (CD31+) cells, 0.80% of cardiomyocytes (MF20+), and 4.0% of fibroblasts (Thy1.1+) at 12 hours post-injection of 60 mg/kg liposomes.
Animal Model: C57BL/6 (10-week-old male, TAC-induced pressure overload)[3]
Dosage: 4 mg/kg
Administration: i.v.; every third day; 7 doses total
Result: Accumulated at nearly double the mean fluorescence intensity in mouse hearts 24 hours post-single intravenous administration compared to non-targeted exosomes.
Significantly ameliorated TAC-induced reductions in left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) at days 28 and 42 post-TAC, and significantly improved left ventricular end-systolic volume (LVV.s), diastolic left ventricular anterior wall thickness (LVAW.d), systolic left ventricular anterior wall thickness (LVAW.s), and left ventricular mass compared to PBS controls.
Reversed TAC-induced mean arterial blood pressure elevation from 116.70 mmHg to 92.37 mmHg.
Significantly reduced serum levels of angiotensin II (Ang II) and N-terminal pro B-type natriuretic peptide (NT-proBNP), and lung wet/dry weight ratio compared to PBS controls.
Significantly reduced TAC-induced increases in heart/body weight ratio, heart weight/tibial length ratio, and relative cardiomyocyte surface area (increased by 30% in PBS-treated TAC mice).
Significantly reduced TAC-induced upregulation of hypertrophic marker genes Acta1, Nppa, Nppb, and the Myh7/Myh6 ratio, and significantly decreased perivascular and myocardial interstitial fibrosis from 19.49% and 16.88% in PBS-treated TAC mice to 2.43% and 1.13%.
Significantly reduced TAC-induced upregulation of hypertrophy-associated proteins β-MHC, BNP, GP130, p-ERK1/2, p-AKT, and p-STAT3 in ventricular tissues.
Restored TAC-induced reduction in cardiac miRNA-148a levels to 252.30% of sham levels (vs.
66.83% in PBS-treated TAC mice).
Molecular Weight

627.76

Formula

C25H45N11O6S
CAS No.
Sequence

Cys-Arg-Pro-Pro-Arg
Sequence Shortening

CRPPR
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Heart-homing peptide Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Heart-homing peptide876460-72-9ExosomesSTATERKAktExtracellular signal regulated kinasesPKBProtein kinase Bheart-targeting peptidecardiovascular diseasesFVB miceC57BL/6miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Heart-homing peptide
Cat. No.:
HY-P10641
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.